Clik here to view.
Seattle Genetics and Astellas Initiate Pivotal Trial of Enfortumab Vedotin...
BOTHELL, Wash. & TOKYO Seattle Genetics, Inc. (NASDAQ: SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced dosing of the first patient...
View ArticleClik here to view.
和铂医药宣布，已授权信达生物制药使用其全人源单克隆抗体转基因小鼠平台开发多种全人源单克隆抗体新药
中国上海，荷兰鹿特丹和美国马萨诸塞州剑桥 和铂医药（Harbour BioMed）宣布，已授权一家中国优秀的创新型生物制药公司信达生物制药（Innovent Biologics, Inc.）使用其拥有全球专利技术的H2L2转基因小鼠平台，开发多领域的全人源单克隆抗体创新药物。...
View ArticleClik here to view.
Harbour BioMed Announces Multi-Year Transgenic Platform Licensing Agreement...
SHANGHAI & ROTTERDAM, The Netherlands & CAMBRIDGE, Mass. Harbour BioMed announced today that it has licensed its patented H2L2 transgenic mouse platform for generating fully human...
View ArticleClik here to view.
Shionogi Inc. and Purdue Pharma L.P. Announce U.S. Availability of Symproic®...
OSAKA, Japan & FLORHAM PARK, N.J. & STAMFORD, Conn. Shionogi Inc. and Purdue Pharma L.P. announced today that Symproic® (naldemedine) 0.2 mg tablets are now available throughout the United...
View ArticleClik here to view.
Takeda Presents Updated Results from Pivotal Phase 2 ALTA Trial of ALUNBRIGTM...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that data from the pivotal Phase 2 ALTA (ALK in Lung Cancer Trial of AP26113) clinical trial...
View ArticleClik here to view.
Foundation Medicine to Present Validation for FoundationOne CDx™, a...
CAMBRIDGE, Mass. Foundation Medicine, Inc. (NASDAQ:FMI) today announced that the company will present validation data for FoundationOne CDx, its comprehensive genomic profiling assay, at the...
View ArticleClik here to view.
Ipsen Announces That Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary...
PARIS Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) and its partner Exelixis (NASDAQ: EXEL) today announced that its global phase 3 CELESTIAL trial met its primary endpoint of overall survival...
View ArticleClik here to view.
Novocure Announces Data Presentations at the IASLC 18th World Conference on...
ST. HELIER, Jersey Novocure (NASDAQ: NVCR) announced today five data presentations at the International Associations for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer,...
View ArticleClik here to view.
武田呈报ALUNBRIGTM (brigatinib)治疗ALK阳性非小细胞肺癌枢纽性2期ALTA试验的更新结果
马萨诸塞州剑桥和日本大阪 (美国商业资讯) — 武田药品工业株式会社(TSE: 4502)今天宣布，枢纽性2期ALTA (ALK in Lung Cancer Trial of AP26113)临床试验数据将于日本标准时间10月16日星期一下午4:30 – 4:40在国际肺癌研究学会(IASLC)第18届世界肺癌大会(WCLC)上进行口述呈报，该试验评估ALUNBRIGTM...
View ArticleClik here to view.
Spectrum Pharmaceuticals Highlights Poziotinib Data in Non-Small-Cell Lung...
HENDERSON, Nev. Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and...
View ArticleClik here to view.
Interim Analysis of Ignyta’s Entrectinib Suggests Potential Best-in-Class...
SAN DIEGO Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, today announced updated results from its clinical trials, including the STARTRK-2 trial, of...
View ArticleClik here to view.
武田薬品がALK陽性非小細胞肺がんでのALUNBRIGTM（ブリガチニブ）のピボタル第2相ALTA試験の最新データを発表
米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） — 武田薬品工業株式会社（TSE: 4502）は本日、クリゾチニブ投与中に進行した局所進行性／転移性未分化リンパ腫キナーゼ（ALK）陽性非小細胞肺がん（NSCLC）患者でALUNBRIGTM（ブリガチニブ）を評価するピボタル第2相ALTA（ALK in Lung Cancer Trial of...
View ArticleClik here to view.
ADCセラピューティクスが登録試験リードプログラム2件の資金2億ドルを私募調達したと発表
スイス・ローザンヌ （ビジネスワイヤ） — 主要ながんを標的にした専有的な抗体薬物複合体（ADC）の開発を専門とするオンコロジー創薬／開発企業のADCセラピューティクス（ADCT）は本日、2億ドルを私募調達したと発表しました。今回の資金調達は応募超過となり、Auven...
View ArticleClik here to view.
Kyowa Hakko Kirin Announces Marketing Authorisation Application for...
TOKYO Kyowa Hakko Kirin Co., Ltd. (TOKYO:4151) (President and CEO: Nobuo Hanai, “Kyowa Hakko Kirin”) today announces that its marketing authorisation application (MAA) for mogamulizumab, for the...
View ArticleClik here to view.
Astellas Reports First Half FY2017 Financial Results, Revises Fiscal Year...
TOKYO Astellas Pharma Inc. (TOKYO:4503) (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced the financial results for the first six months of fiscal year 2017, ending March 31, 2018...
View ArticleClik here to view.
Takeda Reports First Half FY2017 Results
OSAKA, Japan Takeda Pharmaceutical Company Limited (TOKYO:4502): Underlying Revenue growth of 6.7% led by Takeda’s Growth Drivers Underlying Revenue grew +6.7% with solid performances across all...
View ArticleClik here to view.
武田薬品：2017年度上期（4-9月期）の連結業績について
大阪 （ビジネスワイヤ） — 武田薬品工業株式会社 （東証：4502）： 実質的な売上収益は＋6.7％の増収、タケダの成長ドライバーが牽引...
View ArticleClik here to view.
Takeda to Showcase Data That May Reshape the Future of Blood Cancer...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that it will present a total of 11 company-sponsored abstracts at the 59th American Society of...
View ArticleClik here to view.
Altemia™治疗镰状细胞病(SCD)患儿获得临床成功
佛罗里达州里维埃拉海滩 — (美国商业资讯) — Sancilio Pharmaceuticals Company, Inc. (SPCI)今天宣布，一项评估Altemia™口服软明胶胶囊治疗5-17岁镰状细胞病患儿有效性和安全性的临床研究获得阳性先期结果 (https://clinicaltrials.gov/ct2/show/NCT02973360)。...
View ArticleClik here to view.
Celltrion Healthcare Presents Phase III Switching Data Supporting the...
SAN DIEGO New data presented at the 2017 American College of Rheumatology (ACR) Annual Meeting show that CT-P10 is comparable to reference rituximab in terms of efficacy, pharmacodynamics (PD) and...
View Article